pethidine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
analgesics, pethidine derivatives 1690 57-42-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • meperidine
  • pethidine
  • isonipecaine
  • meperidol
  • pethanol
  • pethidin
  • meperidine hydrochloride
  • pethidine hydrochloride
  • meperidine HCl
  • pethidine HCl
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
  • Molecular weight: 247.34
  • Formula: C15H21NO2
  • CLOGP: 2.23
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 29.54
  • ALOGS: -2.35
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P
0.40 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 3.22 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 13 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 60.65 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 52 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.42 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 10, 1942 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 4532.09 14.93 1916 12851 249094 50341263
Contrast media allergy 388.40 14.93 95 14672 1932 50588425
International normalised ratio fluctuation 236.22 14.93 65 14702 2125 50588232
Drug intolerance 196.09 14.93 278 14489 218826 50371531
Bloody discharge 155.58 14.93 41 14726 1133 50589224
Obliterative bronchiolitis 154.58 14.93 45 14722 1808 50588549
Upper respiratory tract infection 132.37 14.93 127 14640 65771 50524586
Psoriasis 123.74 14.93 125 14642 68875 50521482
Lyme disease 116.31 14.93 39 14728 2504 50587853
Myoglobin urine present 99.23 14.93 23 14744 367 50589990
Vomiting 92.23 14.93 319 14448 460439 50129918
Herpes zoster 83.38 14.93 103 14664 70683 50519674
Serotonin syndrome 78.70 14.93 62 14705 24651 50565706
Treatment failure 77.84 14.93 142 14625 137495 50452862
Nausea 64.94 14.93 388 14379 705010 49885347
Urticaria 58.97 14.93 122 14645 129439 50460918
Amylase increased 54.02 14.93 28 14739 5402 50584955
Bronchitis chronic 47.43 14.93 23 14744 3854 50586503
Rheumatoid arthritis 43.58 14.93 144 14623 202406 50387951
Hallucination 42.68 14.93 60 14707 46597 50543760
Toxic encephalopathy 42.48 14.93 24 14743 5491 50584866
Alopecia 41.96 14.93 10 14757 245037 50345320
Hypertension 37.54 14.93 141 14626 211062 50379295
Rash 36.46 14.93 235 14532 437236 50153121
Respiratory arrest 34.23 14.93 43 14724 29966 50560391
Troponin increased 33.96 14.93 24 14743 8094 50582263
Therapeutic product effect incomplete 33.48 14.93 79 14688 91436 50498921
Anaphylactic reaction 32.06 14.93 57 14710 53998 50536359
Condition aggravated 32.00 14.93 24 14743 297034 50293323
Neonatal respiratory depression 28.38 14.93 6 14761 61 50590296
Infusion related reaction 28.30 14.93 111 14656 169446 50420911
Arteriospasm coronary 26.73 14.93 15 14752 3387 50586970
Thrombocytopenia 26.73 14.93 90 14677 127583 50462774
Neonatal seizure 26.30 14.93 8 14759 374 50589983
Skin reaction 24.52 14.93 23 14744 11545 50578812
Moaning 24.39 14.93 9 14758 765 50589592
Pulse absent 24.36 14.93 16 14751 4790 50585567
Extremity contracture 23.49 14.93 10 14757 1238 50589119
Nervous system disorder 23.04 14.93 26 14741 16197 50574160
Pancreatic carcinoma recurrent 21.68 14.93 5 14762 78 50590279
Limb mass 21.58 14.93 12 14755 2663 50587694
Blood lactate dehydrogenase increased 20.68 14.93 27 14740 19535 50570822
Cardiac aneurysm 20.42 14.93 8 14759 801 50589556
Pemphigus 20.36 14.93 5 14762 120161 50470196
Dactylitis 19.68 14.93 10 14757 1851 50588506
Death 19.62 14.93 41 14726 325338 50265019
Product dose omission issue 19.58 14.93 15 14752 183823 50406534
Respiratory alkalosis 19.50 14.93 11 14756 2508 50587849
Blood potassium increased 19.50 14.93 24 14743 16374 50573983
Diarrhoea 17.83 14.93 100 14667 588376 50001981
Lip dry 17.40 14.93 13 14754 4774 50585583
Breath sounds absent 16.37 14.93 5 14762 237 50590120
Gastrointestinal inflammation 15.63 14.93 12 14755 4588 50585769
Systemic lupus erythematosus 15.58 14.93 11 14756 140611 50449746
Encephalopathy neonatal 15.45 14.93 3 14764 19 50590338

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 529.84 16.28 262 5668 68144 29500453
Nightmare 68.35 16.28 37 5893 11380 29557217
Sedation 63.62 16.28 41 5889 17364 29551233
Chills 51.03 16.28 67 5863 71233 29497364
Nephrolithiasis 49.81 16.28 41 5889 25293 29543304
Hyperhidrosis 37.67 16.28 55 5875 64485 29504112
Mucosal atrophy 29.42 16.28 6 5924 76 29568521
Drug dependence 29.33 16.28 28 5902 20953 29547644
Oesophageal mucosa erythema 27.85 16.28 5 5925 30 29568567
Carditis 27.66 16.28 6 5924 104 29568493
Serotonin syndrome 27.62 16.28 25 5905 17487 29551110
Facial wasting 25.77 16.28 6 5924 145 29568452
Nausea 25.58 16.28 120 5810 289135 29279462
Product used for unknown indication 25.06 16.28 7 5923 355 29568242
Motor developmental delay 24.95 16.28 8 5922 652 29567945
Haemorrhoids thrombosed 24.24 16.28 6 5924 189 29568408
Pseudopolyp 23.72 16.28 6 5924 207 29568390
Administration related reaction 23.31 16.28 5 5925 82 29568515
Blood albumin abnormal 23.29 16.28 6 5924 223 29568374
Gastrointestinal tract irritation 23.21 16.28 6 5924 226 29568371
Starvation 23.03 16.28 6 5924 233 29568364
Bone infarction 22.86 16.28 6 5924 240 29568357
Intra-abdominal haemorrhage 22.13 16.28 10 5920 2085 29566512
Drug abuser 21.78 16.28 12 5918 3815 29564782
Gastrointestinal scarring 21.63 16.28 5 5925 117 29568480
Anal stenosis 20.77 16.28 5 5925 140 29568457
Large intestinal stenosis 19.19 16.28 8 5922 1373 29567224
Restrictive cardiomyopathy 17.57 16.28 6 5924 595 29568002
Oedema mucosal 17.18 16.28 6 5924 636 29567961
Oesophagitis ulcerative 16.85 16.28 6 5924 674 29567923
Pancreatitis 16.71 16.28 27 5903 34487 29534110
Dysplasia 16.60 16.28 6 5924 703 29567894
Ileal perforation 16.58 16.28 6 5924 706 29567891
Respiratory arrest 16.49 16.28 23 5907 25810 29542787

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 4413.54 13.92 1802 15123 236013 64245794
Contrast media allergy 312.48 13.92 79 16846 2062 64479745
International normalised ratio fluctuation 228.07 13.92 66 16859 2895 64478912
Bloody discharge 145.90 13.92 40 16885 1437 64480370
Obliterative bronchiolitis 134.86 13.92 43 16882 2622 64479185
Drug intolerance 134.21 13.92 203 16722 187789 64294018
Lyme disease 122.35 13.92 39 16886 2376 64479431
Upper respiratory tract infection 110.83 13.92 115 16810 72670 64409137
Psoriasis 99.78 13.92 108 16817 71595 64410212
Serotonin syndrome 98.51 13.92 82 16843 39200 64442607
Myoglobin urine present 87.21 13.92 22 16903 568 64481239
Vomiting 83.75 13.92 325 16600 550792 63931015
Nausea 75.09 13.92 404 16521 785396 63696411
Urticaria 67.79 13.92 131 16794 147186 64334621
Herpes zoster 59.93 13.92 88 16837 79099 64402708
Infusion related reaction 51.29 13.92 125 16800 164342 64317465
Amylase increased 46.62 13.92 30 16895 9655 64472152
Treatment failure 44.37 13.92 96 16829 116720 64365087
Bronchitis chronic 43.32 13.92 21 16904 3911 64477896
Rheumatoid arthritis 41.10 13.92 115 16810 164179 64317628
Hypertension 37.63 13.92 151 16774 259110 64222697
Nightmare 35.25 13.92 35 16890 20958 64460849
Rash 35.22 13.92 223 16702 458326 64023481
Respiratory arrest 34.59 13.92 55 16870 52930 64428877
Chills 34.23 13.92 96 16829 137168 64344639
Toxic encephalopathy 32.16 13.92 24 16901 9791 64472016
Therapeutic product effect incomplete 30.48 13.92 77 16848 103405 64378402
Hallucination 28.98 13.92 61 16864 72727 64409080
Drug abuser 27.97 13.92 18 16907 5790 64476017
Nephrolithiasis 26.68 13.92 44 16881 43639 64438168
Troponin increased 26.46 13.92 26 16899 15373 64466434
Death 25.94 13.92 55 16870 482650 63999157
Pain 24.54 13.92 237 16688 553274 63928533
Moaning 22.94 13.92 9 16916 1007 64480800
Anaphylactic reaction 22.24 13.92 53 16872 68611 64413196
Extremity contracture 21.98 13.92 10 16915 1615 64480192
Hyperhidrosis 21.60 13.92 77 16848 124843 64356964
Condition aggravated 21.21 13.92 41 16884 372385 64109422
Pancreatic carcinoma recurrent 20.67 13.92 5 16920 108 64481699
Sedation 20.43 13.92 38 16887 41424 64440383
Administration related reaction 19.93 13.92 5 16920 126 64481681
Alopecia 18.82 13.92 10 16915 165680 64316127
Infection 18.79 13.92 97 16828 184783 64297024
Limb mass 18.73 13.92 11 16914 3010 64478797
Disease progression 18.52 13.92 7 16918 141673 64340134
Lip dry 18.32 13.92 13 16912 4905 64476902
Emotional distress 17.72 13.92 33 16892 36005 64445802
Cardiac aneurysm 17.59 13.92 8 16917 1291 64480516
Product used for unknown indication 17.51 13.92 7 16918 823 64480984
Drug dependence 17 13.92 31 16894 33281 64448526
Breath sounds absent 16.58 13.92 5 16920 253 64481554
General physical health deterioration 16.03 13.92 18 16907 204407 64277400
Cholelithiasis 15.69 13.92 36 16889 45470 64436337
Blood potassium increased 15.63 13.92 26 16899 25954 64455853
Product dose omission issue 15.43 13.92 17 16908 194730 64287077
Pulse absent 15.17 13.92 15 16910 8931 64472876
Neutropenia 14.86 13.92 25 16900 239599 64242208
Thrombocytopenia 14.80 13.92 105 16820 223696 64258111
Joint swelling 14.80 13.92 102 16823 215280 64266527
Drug withdrawal syndrome 14.57 13.92 28 16897 31263 64450544
Cytokine release syndrome 14.11 13.92 22 16903 20807 64461000

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02AB02 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Phenylpiperidine derivatives
ATC N02AB52 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Phenylpiperidine derivatives
ATC N02AB72 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Phenylpiperidine derivatives
ATC N02AG03 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Opioids in combination with antispasmodics
MeSH PA D000759 Adjuvants, Anesthesia
MeSH PA D000700 Analgesics
MeSH PA D000701 Analgesics, Opioid
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D009294 Narcotics
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35482 narcotic analgesic
CHEBI has role CHEBI:53784 antispasmodics
CHEBI has role CHEBI:55322 mu-opioid agonists
CHEBI has role CHEBI:59282 kappa-opioid receptor agonists
FDA MoA N0000175684 Full Opioid Agonists
FDA EPC N0000175690 Opioid Agonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000
General anesthesia indication 50697003
Severe pain indication 76948002
Labor pain indication 247412007
Local anesthesia indication 386761002
Sedation as Adjunct to Anesthesia indication
Dependent drug abuse contraindication 6525002
Necrosis contraindication 6574001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Hyperbilirubinemia contraindication 14783006 DOID:2741
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Agranulocytosis contraindication 17182001 DOID:12987
Jaundice contraindication 18165001
Lowered convulsive threshold contraindication 19260006
Disorder of the central nervous system contraindication 23853001 DOID:331
Alcohol intoxication contraindication 25702006
Gangrene contraindication 36024000
Hypothyroidism contraindication 40930008 DOID:1459
Myxedema contraindication 43153006 DOID:11634
Low blood pressure contraindication 45007003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Thrombophlebitis contraindication 64156001 DOID:3875
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Poisoning by acetaminophen contraindication 70273001
Sleep apnea contraindication 73430006 DOID:0050847
Extrapyramidal disease contraindication 76349003
Urethral stricture contraindication 76618002
Decreased respiratory function contraindication 80954004
Disorder of brain contraindication 81308009 DOID:936
Injury of head contraindication 82271004
Chronic idiopathic constipation contraindication 82934008
Cor pulmonale contraindication 83291003 DOID:8515
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Gastrointestinal obstruction contraindication 126765001
Hb SS disease contraindication 127040003 DOID:10923
Seizure disorder contraindication 128613002
Drug-induced psychosis contraindication 191483003 DOID:1742
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Pheochromocytoma contraindication 302835009
Bone marrow depression contraindication 307762000
Coma contraindication 371632003
Primary adrenocortical insufficiency contraindication 373662000
Angle-closure glaucoma contraindication 392291006 DOID:13550
Breastfeeding (mother) contraindication 413712001
Central nervous system depression contraindication 418072004
Acute exacerbation of asthma contraindication 708038006
Injection Site Sequelae contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mu-type opioid receptor GPCR AGONIST Ki 6.04 CHEMBL CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.49 CHEMBL
Sodium-dependent dopamine transporter Transporter WOMBAT-PK
Kappa-type opioid receptor GPCR Ki 5.63 WOMBAT-PK
Glutamate receptor ionotropic, NMDA 3A Ion channel WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 4.65 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.39 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 4.75 CHEMBL
Mu-type opioid receptor GPCR Ki 6.35 CHEMBL
Opioid receptor GPCR EC50 6.15 CHEMBL
Opioid receptor GPCR IC50 6.30 CHEMBL

External reference:

IDSource
4019813 VUID
N0000147902 NUI
D01383 KEGG_DRUG
50-13-5 SECONDARY_CAS_RN
4018030 VANDF
4019813 VANDF
C0025376 UMLSCUI
CHEBI:6754 CHEBI
CHEMBL1701 ChEMBL_ID
CHEMBL607 ChEMBL_ID
DB00454 DRUGBANK_ID
4058 PUBCHEM_CID
7221 IUPHAR_LIGAND_ID
9E338QE28F UNII
103755 RXNORM
1858 MMSL
5046 MMSL
d00017 MMSL
001542 NDDF
004620 NDDF
2878005 SNOMEDCT_US
387298007 SNOMEDCT_US
54544005 SNOMEDCT_US
D008614 MESH_DESCRIPTOR_UI
411 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-3545 SOLUTION 50 mg ORAL ANDA 32 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-4595 TABLET 50 mg ORAL ANDA 32 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-4596 TABLET 100 mg ORAL ANDA 32 sections
Meperidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-8595 TABLET 50 mg ORAL ANDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1176 INJECTION, SOLUTION 25 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1176 INJECTION, SOLUTION 25 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1178 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1178 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1179 INJECTION, SOLUTION 75 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1179 INJECTION, SOLUTION 75 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1180 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1180 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1181 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1181 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1201 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1201 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1203 INJECTION, SOLUTION 25 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1203 INJECTION, SOLUTION 25 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1253 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1253 INJECTION, SOLUTION 50 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1254 INJECTION, SOLUTION 75 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1254 INJECTION, SOLUTION 75 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1255 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1255 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1256 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1256 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 32 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1362 INJECTION, SOLUTION 25 mg INTRAMUSCULAR NDA 35 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1362 INJECTION, SOLUTION 25 mg INTRAMUSCULAR NDA 35 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1362 INJECTION, SOLUTION 25 mg INTRAMUSCULAR NDA 35 sections
DEMEROL HUMAN PRESCRIPTION DRUG LABEL 1 0409-1377 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 35 sections